MedTrace Logo

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-09-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels

Conditions

  • Blepharitis

Interventions

DRUG

AzaSite®

Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days

Sponsors & Collaborators

Principal Investigators

  • Reza Haque, MD · Sponsor GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00629941 on ClinicalTrials.gov